Athira Pharma Holds Shareholder Meeting, Approves Equity Plan

The biopharmaceutical company's shareholders voted on proposals related to share issuances and a new equity incentive plan.

Mar. 19, 2026 at 3:04am

Got story updates? Submit your updates here. ›

Athira Pharma, a clinical-stage biopharmaceutical company based in Seattle, Washington, held an extraordinary general meeting of shareholders in a virtual format. The meeting addressed six proposals, including share issuances, a new 2026 equity incentive plan, and an increase in authorized common stock. The proposals were approved by a majority of shareholders, according to preliminary results reported during the meeting.

Why it matters

As a clinical-stage biotech company, Athira Pharma's ability to issue new shares and implement an equity incentive plan are important for raising capital, attracting and retaining talent, and funding the development of its pipeline of potential treatments for neurodegenerative diseases.

The details

The meeting was led by Chairperson of the Board Kelly Romano, with President, CEO, and Board Member Mark Litton also participating. The company's outside legal counsel, Michael Nordtvedt of Wilson Sonsini Goodrich & Rosati, served as secretary and kept the meeting minutes. Shareholders were able to vote through the virtual meeting portal if they had not already submitted proxy votes prior to the meeting.

  • The special meeting was held on March 19, 2026.
  • The record date for eligible voters was January 27, 2026.
  • The proxy statement was dated February 23, 2026.

The players

Kelly Romano

Chairperson of the Board of Athira Pharma.

Mark Litton

President, CEO, and Board Member of Athira Pharma.

Michael Nordtvedt

Outside legal counsel from Wilson Sonsini Goodrich & Rosati, serving as secretary of the meeting.

Athira Pharma, Inc.

A clinical-stage biopharmaceutical company headquartered in Seattle, Washington, that is developing therapies for neurodegenerative diseases.

Got photos? Submit your photos here. ›

What they’re saying

“The final voting results would be tallied by the Inspector of Election and disclosed in a Form 8-K to be filed with the Securities and Exchange Commission within four business days of the meeting.”

— Kelly Romano, Chairperson of the Board

What’s next

The final voting results from the meeting will be disclosed in a Form 8-K filing with the SEC within four business days.

The takeaway

Athira Pharma's ability to raise capital, attract talent, and fund its pipeline of potential neurodegenerative disease treatments was bolstered by shareholder approval of the proposals at the extraordinary general meeting.